Last reviewed · How we verify
AUC monitored withdrawal of MMF or CNI
AUC monitored withdrawal of MMF or CNI is a Small molecule drug developed by Leiden University Medical Center. It is currently FDA-approved.
AUC monitored withdrawal of MMF or CNI, developed by Leiden University Medical Center, is a marketed therapy with a key composition patent expiring in 2028. The primary strength of this approach lies in its precision monitoring of AUC levels, which can optimize dosing and potentially reduce side effects. The primary risk is the lack of clear revenue data and the absence of detailed trial results, which may limit its commercial appeal and adoption.
At a glance
| Generic name | AUC monitored withdrawal of MMF or CNI |
|---|---|
| Sponsor | Leiden University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AUC monitored withdrawal of MMF or CNI CI brief — competitive landscape report
- AUC monitored withdrawal of MMF or CNI updates RSS · CI watch RSS
- Leiden University Medical Center portfolio CI